Idinvest, Gimv-backed Prosensa soars after IPO
The Dutch biotech company is now valued at around $670 million, after its shares gained 48 percent in their first day of trading.
19 September 2013•2 mins read
The Dutch biotech company is now valued at around $670 million, after its shares gained 48 percent in their first day of trading.
